ACDIMA owns 43.9% in the share capital of Shamra Pharma,which amounts to SYP 164.640,000 million.Company production was suspended since June,2012, due to the prevailing circumstances in Syria. ACDIMA’s Board of Directors took a resolution to allocate an “investment impairment provision” for the whole investment value of this company,in accordance with the generally accepted accounting standards